Subcutaneous delivery of poly(oxazoline) polymer conjugates
AssigneeSerina Therapeutics, Inc.
InventorsRandall MOREADITH, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Welmer, Bekir Dizman, Tacey Viegas
Life of this patent
Estimating the term…
Abstract
The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
Claims29
A poly(oxazoline) polymer conjugate, the poly(oxazoline) polymer conjugate comprising an agent linked to the poly(oxazoline) polymer by a linker, wherein the linker has the structure
- wherein R3 is a forms a linkage with the poly(oxazoline) polymer chain;
- R4 is —R6—R7—R8—;
- R6 is a substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl,
- R7 is a group containing a hydrolyzable moiety;
- R8 is absent or is O, S, CRc, or NRc;
- and
- Rc is H or substituted or unsubstituted alkyl.
A poly(oxazoline) polymer conjugate, wherein the poly(oxazoline) polymer conjugate has the formula
- wherein
- R is an initiating group;
- POZ is a poly(oxazoline) polymer of the formula —{[N(COX)CH2CH2]o—[N(COR1)CH2CH2]m}a—, wherein R1 is H, alkyl or substituted alkyl, X is a pendent moiety containing a functional group capable of forming a linkage with the linker or the agent, o is an integer from 1 to 50 and m is an integer from 1 to 950;
- L is
- wherein R3 is a linker linking L to the polymer chain, R4 is —R6—R7—R8—, R6 is a substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl, R7 is a group containing a hydrolyzable moiety, R8 is absent or is O, S, CRc, or NRc, and Rc is H or substituted or unsubstituted alkyl;
- A is an agent;
- a is 1 to 50;
- and
- Nuc is a terminating nucleophile.
A method for treating a disease or condition related to dopamine insufficiency in the peripheral or central nervous system, the method comprising the step of administering to the subject an amount of a poly(oxazoline) polymer conjugate containing a dopamine agonist, the dopamine agonist linked to the polymer by a linker, wherein the linker has the structure
- wherein R3 is a forms a linkage with the poly(oxazoline) polymer chain;
- R4 is —R6—R7—R8—;
- R6 is a substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl;
- R7 is a group containing a hydrolyzable moiety, R8 is absent or is O, S, CRc, or NRc;
- and
- Rc is H or substituted or unsubstituted alkyl.
Dependencies are inferred from the claim text.